Results 91 to 100 of about 405 (131)

Sickle Cell Disease: Treatment Options of the Past, Present, and Future. [PDF]

Am J Nurs
Jacobs-McFarlane CT, Liu A.
europepmc   +1 more source

Doubling down on PK activation for sickle cell disease. [PDF]

Blood Adv
Wilson SR, Pecker LH.
europepmc   +1 more source

Transfusion strategies in hemoglobinopathies: what the latest update of Good Practices tells us in the era of new therapeutic advances. [PDF]

Blood Transfus
Schieppati F.
europepmc   +1 more source

From Mutation to Manifestation: Evaluation of a <i>PKLR</i> Gene Truncation Caused by Exon Skipping in a Schnauzer Terrier. [PDF]

Animals (Basel)
Ma TY, Kuo CJ, Liu PC.
europepmc   +1 more source

Metabolomic Investigation of Myelodysplastic Syndromes, Multiple Myeloma, and Homozygous β-Thalassemia. [PDF]

Cells
Chatzikalil E, Bistas K, Kymioni V, Diamantopoulos PT, Solomou EE.   +4 more
europepmc   +1 more source

Pyruvate kinase deficiency modifies sickle hemoglobin carrier and sickle cell disease phenotypes in mice. [PDF]

JCI Insight
Wang X, Smith M, Kamimura S, Li Q, Shah N, Quezado M, Almeida LE, Vogel S, Tegegn MB, Sun KY, Villasmil R, Liu C, Eaton WA, Thein SL, Quezado ZM.   +14 more
europepmc   +1 more source

Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies. [PDF]

Hemasphere
Farmakis D, Angastiniotis M, Eleftheriou A.   +2 more
europepmc   +1 more source

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease.

Blood
Parekh DS, Eaton WA, Thein SL.
europepmc   +1 more source

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease. [PDF]

Cells
Barak M, Hu C, Matthews A, Fortenberry YM.   +3 more
europepmc   +1 more source